F-fluoromethylcholine(CHO) and PSMA PET/CT for the purpose of restaging. Theaim of the study was to compare the diagnostic performanceof the novel tracer with that of CHO. On a patient basis, thedetectionrates were 70.3 % and 86.5 % for CHO and PSMA,respectively. PSMA also showed a better performance at lowPSA values. The authors conclude that PSMA PET/CT candetectPCarelapseandmetastasiswithsignificantlyimprovedcontrast when compared with CHO PET/CT. This advantageis related to higher tracer uptake by PCa lesions and lowbackground signal, which allow the detection of small lymphnode, bone and liver metastases. Although innovative andinteresting, this study had some limitations: it was retrospec-tive; few lesions wereconfirmed byhistology;several criteriawere used to validate the uptake areas; the results were com-pared against CHO PET/CT, which was considered as astandard even though this modality is not established; and,finally, the impact on patient management is not discussed.The limitations of the study preclude recommendation ofthisnewradiopharmaceutical inoncological guidelines,afatethat has befallen many other promising PET tracers. This is acriticalissue forthefutureofnuclear medicineanddeservesacommentary. The way we introduce new radiopharmaceuti-cals into the clinical arena is highly influenced by publisheddata and we believe that efforts are needed to enhance theimpact of our reports in the world of oncology.Althoughmany readers are wellaware ofPCa imaging,letus briefly summarize the state of the art of PETradiopharma-ceuticals that are used to study PCa.PCa is a considerable health issue and has displayed anincreasing incidence worldwide during the last decade [2] – atrend that justifies the burgeoning medical interest in thisdisease. We can say that PCa is studied as much in men asbreast cancer is studied in, mostly, women. As always inoncology, accurate detection of disease spread is crucial fortreatment decisions and imaging could play a major role inidentifyingtumourextension,providedthatsufficientdiagnos-ticaccuracyisproperlydemonstrated.Ofcourse,PETimagingis competing on many levels with other diagnostic modalities,but we will not cover these aspects. As a consequence of thegreat clinical interest in PCa, several PET radiopharmaceuti-calshavebeeninvestigatedfortheirabilitytodetectthedisease[3].Theroleofthe“pan-tumour”radiopharmaceuticalFDG islimited, mainly due to its low sensitivity, particularly in pa-tients with a low Gleason score, low serum PSA values andlocalizeddisease[4].However,ithasbeensuggestedthatFDGmay be useful when applied in specific clinical settings, suchasinstaginghigh-riskpatients,intheassessmentofthespreadof hormone-resistant disease, in the evaluation of treatmentresponse, and in the assessment of prognosis in patients withmetastatic PCa [5]. Nevertheless, the limited availability ofevidence means that it is difficult to go beyond the hypothesisof a possible utility of FDG in aggressive disease.Among the different PET tracers proposed for PCa,choline derivatives are the most commonly used, especially inpatients with biochemical failure [6]. Acetate and CHO have